Stoke Therapeutics STOK 深 沪
等待开盘 05-21 09:30:00 美东时间
30.295
+0.335
+1.12%
华盛通- 最 高30.42
- 今 开30.00
- 成交量 69.17万股
- 最 低 29.26
- 昨 收 29.96
- 总市值 18.87亿
- 52周最高 40.22
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 9.47
- 委 比 -72.45%
- 总股本 6228.17万
- 历史最高 71.58
- 量 比 0.99
- 振 幅 3.87%
- 历史最低 3.35
- 每 手 1
- 风险率 8.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported progress on its NVG-291 clinical development, including FDA alignment on the RESTORE study parameters for chronic tetraplegia, ongoing CONNECT SCI biomechanical gait analyses, and plans to initiate the RESTORE study in mid-2026. The company listed on Nasdaq under 'NGEN' and strengthened its leadership team with key senior appointments. Financially, NervGen ended Q1 2026 with $16.6M in cash and investments, increased ...
05-18 11:15
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target
BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.
05-11 17:52
Stoke Therapeutics Q1 EPS $(0.79) Beats $(0.84) Estimate, Sales $6.229M Beat $5.880M Estimate.
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.84) by 5.95 percent. This is a 141.58 percent decrease over earnings of $1.90 per share
05-08 04:04
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
U.S. RESEARCH ROUNDUP- Air Products, Chevron, Fedex
U.S. RESEARCH ROUNDUP- Air Products, Chevron, Fedex March 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Air Products, Chevron and Fedex on Friday. HIGHLIGHTS * Air Products APD.N : JP Morgan raises to overweight fro
03-20 14:50
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased Ichor's PT to $55, Needham raised Semtech's PT to $105, HC Wainwright cut Eupraxia Pharma's PT to $11, Evercore ISI Group raised National Storage Affiliates Trust's PT to $41.
03-17 19:49
Needham Maintains Buy on Stoke Therapeutics, Raises Price Target to $40
Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $35 to $40.
03-17 19:13
